Black Rock Inc. Avrobio, Inc. Transaction History

Black Rock Inc.

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 10, 2024	SELL	$1.15 - $1.48 $1,467 - $1,888	-1,276 Reduced 0.21%	613,432 $785,000
Q4 2023 Feb 13, 2024	SELL	$1.22 - $1.62 $9,570 - $12,708	-7,845 Reduced 1.26%	614,708 $836,000
Q3 2023 Nov 13, 2023	SELL	$0.98 - $1.62 $10,273 - $16,982	-10,483 Reduced 1.66%	622,553 $958,000
Q2 2023 Aug 11, 2023	SELL	$0.58 - $1.31 $440,993 - $996,036	-760,333 Reduced 54.57%	633,036 $601,000
Q1 2023 May 12, 2023	SELL	$0.76 - $1.82 $96,497 - $231,087	-126,971 Reduced 8.35%	1,393,369 $1.39 Million
Q4 2022 Feb 13, 2023	SELL	$0.64 - $0.91 $309,267 - $439,740	-483,231 Reduced 24.12%	1,520,340 $1.08 Million
Q3 2022 Nov 14, 2022	BUY	$0.68 - $1.11 $1,732 - $2,828	2,548 Added 0.13%	2,003,571 $1.29 Million
Q2 2022 Aug 12, 2022	SELL	$0.75 - $1.33 $1.34 Million - $2.38 Million	-1,787,704 Reduced 47.18%	2,001,023 $1.84 Million
Q1 2022 May 12, 2022	BUY	$1.29 - $4.04 $429,104 - $1.34 Million	332,639 Added 9.62%	3,788,727 $5 Million
Q4 2021 Feb 10, 2022	SELL	$3.45 - $6.05 $546,366 - $958,120	-158,367 Reduced 4.38%	3,456,088 $13.3 Million
Q3 2021 Nov 09, 2021	BUY	$5.53 - $9.28 $440,713 - $739,569	79,695 Added 2.25%	3,614,455 $20.2 Million
Q2 2021 Aug 11, 2021	BUY	$7.84 - $12.6 $27.7 Million - $44.5 Million	3,534,760 New	3,534,760 $31.4 Million

559K

Ticker AVRO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,773,900
Description
AVROBIO, Inc., a clinical-stage gene therapy company, develops ex vivo lentiviral-based gene therapies to treat rare diseases following a single dose worldwide. Its gene therapies employ hematopoietic stem cells that are collected from patients and modified with a lentiviral vector to insert functional copies of the gene that is defective in the...

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

Stay updated on Black Rock Inc. with notifications on news.